Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Abroad (travel likely)RecruitingPHASE2
Conditions
Extramedullary Disease in Multiple Myeloma · Recurrent Multiple Myeloma · Refractory Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Roswell Park Cancer Institute, Buffalo, New York, United States
Contact: Principal Investigator (Jens Hillengass)
Study leads
Jens Hillengass, MD
Principal Investigator
Roswell Park Comprehensive Cancer Center